Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Osteoporosis treatment osteoclast differentiation

The study of osteoclast differentiation is important for understanding potential new treatments for osteoporosis. Such therapies are typically explored in tissue culture models such as the Raw264 mouse monocytic cell line, which is capable of differentiation into functional multinuclear osteoclasts after treatment with the cytokine Rankl. Use of transformed cell lines raises the concern that results may not be extrapolated to normal tissue. To address this question, the transcriptional responses for Rankl treatment of the Raw264 cell line, and of two ex vivo primary cell systems (bone marrow macrophages, and hematopoetic stem cells) were compared using Affymetrix GeneChips [23]. The models proved to... [Pg.421]

Strontium ranelate has not been approved in the United States for the treatment of osteoporosis but is being used in Europe, generally at a dose of 2 g/d. Denosumab, an antibody to RANKL that suppresses bone resorption by interfering with RANKL/RANK induction of osteoclast differentiation and function, has shown good efficacy in phase 3 trials and may be approved for clinical use in the near future. [Pg.972]

In addition. Das et ah demonstrated the effects of fucoxanthin on osteoclastogenesis. Treatment with 2.5 M fucoxanthin also induced apoptosis accompanied by activation of caspase-3 in osteoclast-like cells. Those in vitro studies suggest that fucoxanthin suppresses osteoclastogenesis via the inhibition of osteoclast differentiation and the induction of apoptosis in osteoclasts (Das et ah, 2010). Hence, dietary fucoxanthin may be useful for the prevention of bone diseases such as osteoporosis and rheumatoid arthritis, which are known to be related to bone resorption. [Pg.49]

An inhibitor of osteoclast differentiation and / or function is expected to be useful for treatment of bone lytic diseases such as osteoporosis, rheumatoid arthritis, and tumor metastasis into bone. Paenol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38, and NF-kB pathway (Tsai et ah, 2008). S)unbioimine (Fig. 32.2A) from the symbiotic marine dinoflagellate Symbiodinium sp. exhibits inhibitory effect on osteoclast differentiation (Kita et ah, 2004). [Pg.422]

Falls SSRIs and serotonin and noradrenalin reuptake inhibitors (SNRIs) have long been linked with an increased risk of osteopenia/osteoporosis potentiating falls and fractures, especially in tiie elderly. A biological mechanism for these risks associated with SSRIs has been idenhfied. Studies have demonstrated a reduction in osteoblast proliferation and activity following treatment with SSRIs, the magnitude of such effects being linked to affinity to the serotonin transporter. In addition, recent research examining serotonin receptor expression in human osteoblasts and osteoclasts has found that SSRIs differentially inhibit bone cells via apoptosis [10 ]. [Pg.14]

Some herbs are used in bone fracture treatment as well as osteoporosis. The studies of Sun et al. 2002 and Jeong et al. 2005 [4, 5] showed that Gu-Sui-Bu has potential effects on primary and secondary bone cells culture. The herbal extract enhanced proliferation and differentiation of bone cell in the studies. On the other hand, the crude extract has been proven possessing inhibition effect on osteoclast obtained from fetal mouse long bone [6]. [Pg.819]


See other pages where Osteoporosis treatment osteoclast differentiation is mentioned: [Pg.200]    [Pg.965]    [Pg.282]    [Pg.282]    [Pg.329]    [Pg.543]    [Pg.2101]    [Pg.175]    [Pg.143]   
See also in sourсe #XX -- [ Pg.123 , Pg.422 ]




SEARCH



Osteoclasts

Osteoclasts differentiation

Osteoporosis

Osteoporosis treatment

© 2024 chempedia.info